Brainsway Appoints CEO

Brainsway Ltd., developer of advanced noninvasive treatments for brain disorders, has appointed Yaacov Michlin as CEO. 

Michlin brings two decades of experience in growing biomedical organizations. His proficiency in corporate finance, capital markets and business management and development has played a crucial role in his ability to lead organizations throughout the biotech industry, according to company executives. He joined Brainsway in 2015, serving as a director on its board.
 
“We are pleased to welcome Yaacov as CEO, following a rigorous selection process, as he brings extensive expertise in steering biomedical companies to success,” said Dr. David Zacut, chairman at Brainsway. “Yaacov possesses the right blend of strategic acumen, interpersonal skills, relationship assets and management capabilities necessary to maximize Brainsway’s technological potential and human talent. We are confident that these factors will enable the company to achieve its objectives and that Yaacov will succeed in positioning Brainsway as the global growth engine for the treatment of brain disorders.”
 
For the past seven years, Michlin has served as president and CEO of Yissum, the technology transfer company of Israel’s Hebrew University in Jerusalem. At Yissum, he facilitated and oversaw numerous major corporate transactions and initiatives in partnership with corporations worldwide. Michlin also currently serves as chairman of the board for three biotech companies: Integra Holdings, a healthcare investment company; Avraham Pharmaceuticals, a developer of neurodegenerative treatment and prevention products; and Agrinnovation, an agritech fund.
 
Prior to Yissum, Michlin practiced as a corporate lawyer, advising on major corporate matters including mergers and acquisitions, capital raising and initial public offerings for clients including Teva Pharmaceutical Industries. Michlin previously served as chairman for QLIGHT Nanotech Ltd., a developer of semiconductors and nanocrystals, which he led from the company’s founding until its acquisition by Merck. He also served as co-chairman of ITTN, an organization which facilitates the commercialization of Israeli technologies.
 
Michlin is a lawyer and economist by training, and holds an M.B.A. from the Technion in high-tech company management. 
 
Brainsway
 develops noninvasive treatments for brain disorders using deep transcranial magnetic stimulation (Deep TMS). Its patented technology was developed in collaboration with the National Institute of Health (NIH) and is U.S. Food and Drug Administration- and CE-cleared to treat patients with depression who are not currently responding to medication. The company is based in Jerusalem and has a U.S. office in Hackensack, N.J.